Sheeja Aravindan to Disease Progression
This is a "connection" page, showing publications Sheeja Aravindan has written about Disease Progression.
Connection Strength
0.578
-
Emerging therapeutic targets for neuroblastoma. Expert Opin Ther Targets. 2020 09; 24(9):899-914.
Score: 0.150
-
Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs. Cell Biol Toxicol. 2021 06; 37(3):461-478.
Score: 0.150
-
Targeting acquired oncogenic burden in resilient pancreatic cancer: a novel benefit from marine polyphenols. Mol Cell Biochem. 2019 Oct; 460(1-2):175-193.
Score: 0.138
-
De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution. Sci Rep. 2019 08 13; 9(1):11766.
Score: 0.035
-
Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. Oncotarget. 2016 Apr 05; 7(14):18605-19.
Score: 0.027
-
RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes. Oncotarget. 2015 Nov 03; 6(34):36522-34.
Score: 0.027
-
Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes. BMC Cancer. 2015 Jul 10; 15:514.
Score: 0.026
-
Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells. BMC Genomics. 2015 Jul 07; 16:501.
Score: 0.026